Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma

Volume 25, Issue 1, 2020, pp. 47-55
DOI: 10.1615/CritRevOncog.2020034985
Get accessGet access

ABSTRACT

Liver cancer is the 6th leading cause of cancer related deaths in the US even though it ranks 14th in incidence. More men are diagnosed with liver cancer than women, and the number of projected deaths among men (20,020) is almost double that among women (10,140) in the US. Infections like hepatitis and metabolic conditions like obesity are believed to be major risk factors for the onset of liver cancer. Hepatocellular carcinoma (HCC), the most common type of liver cancer, accounts for 75% of all cases. Chemotherapy has not been effective in treating HCC. Targeted therapies are being used in advanced HCC patients due to a better survival and less side effects when compared to traditional chemotherapy. Therapeutic agents targeting the regulators of growth factor signaling pathways and the mediators of downstream signaling−for example, inhibitors of the tyrosine kinase receptor−are used as targeted molecular therapies. Kinase inhibitors that modulate growth signals, such as sorafenib and lenvatinib, are commonly employed in targeted molecular therapy for HCC patients. This review covers these agents, highlighting modes of action and providing details on clinical trials.

REFERENCES
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. PubMed PMID: 30207593. Epub 2018/09/13.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. PubMed PMID: 31912902. Epub 2020/01/09.

  3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001 Sep;2(9):533-43. PubMed PMID: 11905707. Epub 2002/03/22.

  4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16. PubMed PMID: 15508102. Epub 2004/10/28.

  5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011 Sep 22;365(12):1118-27. PubMed PMID: 21992124. Epub 2011/10/14.

  6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010 May;51(5):1820-32. PubMed PMID: 20432259. Epub 2010/05/01.

  7. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: Consensus and controversies. Hepatology. 2003 Oct;38(4):793-803. PubMed PMID: 14512865. Epub 2003/09/27.

  8. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. PubMed PMID: 28694740. PMCID: PMC5490340. Epub 2017/07/12.

  9. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol. 2013 Jul;47(Suppl):S2-S6. PubMed PMID: 23632345. PMCID: PMC3683119. Epub 2013/05/02.

  10. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014 Mar 4;160(5):293-300. PubMed PMID: 24737271. PMCID: PMC4562398. Epub 2014/04/17.

  11. Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017 Jul 8;67(4):273-89. PubMed PMID: 28586094. Epub 2017/06/07.

  12. Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992.

  13. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58. PubMed PMID: 20628345. PMCID: PMC3926946. Epub 2010/07/16.

  14. Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, Kamachi H, Taketomi A. Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma. World J Surg Oncol. 2013 Mar 2;11:52. PubMed PMID: 23452898. PMCID: PMC3599395. Epub 2013/ 03/05.

  15. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. Impact of sex on the survival of patients with hepatocellular carcinoma: A surveillance, epidemiology, and end results analysis. Cancer. 2014 Dec 1;120(23):3707-16. PubMed PMID: 25081299. Epub 2014/08/02.

  16. Cho SJ, Yoon JH, Hwang SS, Lee HS. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol. 2007Aug;22(8):1226-31. PubMed PMID: 17498220. Epub 2007/05/15.

  17. Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakel-lariou S, Kykalos S, Tsourouflis G, Garmpi A, Della-detsima I, Kontzoglou K, Kouraklis G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017 Aug 7;23(29):5282-94. PubMed PMID: 28839428. PMCID: PMC5550777. Epub 2017/ 08/26.

  18. Franco RA, Fan Y, Jarosek S, Bae S, Galbraith J. Racial and geographic disparities in hepatocellular carcinoma outcomes. Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S8. PubMed PMID: 30670200. PMCID: PMC6708601. Epub 2019/01/24.

  19. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. PubMed PMID: 21351269. Epub 2011/02/26.

  20. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907-17. PubMed PMID: 14667750. Epub 2003/12/12.

  21. Gholam P. The role of sorafenib in hepatocellular carcinoma. Gastroenterol Hepatol (NY). 2015 Apr;11(4):253- 5. PubMed PMID: 27099597. PMCID: PMC4836596. Epub 2016/04/22.

  22. Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis. 2011;29(3): 289-302. PubMed PMID: 21829020. Epub 2011/08/11.

  23. Kudo M. Targeted therapy for liver cancer: Updated review in 2012. Curr Cancer Drug Targets. 2012 Nov 1;12(9): 1062-72. PubMed PMID: 22920326. Epub 2012/08/28.

  24. Frenette CT. Increasing awareness on racial disparities in liver transplantation for hepatocellular carcinoma in the United States. Hepatol Commun. 2019 Jan;3(1):5-7. PubMed PMID: 30619989. PMCID: PMC6312649. Epub 2019/01/09.

  25. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012 May 8;4:19-37. PubMed PMID: 24367230. PMCID: PMC3846594. Epub 2012/01/01.

  26. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia. 2003 Jul; 17(7): 1263-93. PubMed PMID: 12835716. Epub 2003/07/02.

  27. Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012 Nov 14;18(42):6005-17. PubMed PMID: 23155330. PMCID: PMC3496878. Epub 2012/11/17.

  28. Walker S, Wankell M, Ho V, White R, Deo N, Devine C, Dewdney B, Bhathal P, Govaere O, Roskams T, Qiao L, George J, Hebbard L. Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. PLoS One. 2019;14(2):e0212860. PubMed PMID: 30794695. PMCID: PMC6386388. Epub 2019/02/23.

  29. Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 2020 Feb 20; 12(2). PubMed PMID: 32093152. PMCID: PMC7072513. Epub 2020/02/26.

  30. Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017 Mar;13(3): 1041-7. PubMed PMID: 28454211. PMCID: PMC5403244. Epub 2017/04/30.

  31. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017 Mar;96(9):e5904. PubMed PMID: 28248853. PMCID: PMC5340426. Epub 2017/03/02.

  32. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002 Oct;8(10):873-83. PubMed PMID: 12360427. Epub 2002/10/03.

  33. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. PubMed PMID: 19095497. Epub 2008/12/20.

  34. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. PubMed PMID: 16908937. Epub 2006/08/16.

  35. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008 0ct;7(10):3129-40. PubMed PMID: 18852116. Epub 2008/10/15.

  36. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Avina J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013 Oct 1;31(28):3517-24. PubMed PMID: 23980084. Epub 2013/08/28.

  37. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol. 2015 Jan 10;33(2):172-9. PubMed PMID: 25488963. PMCID: PMC4279237. Epub 2014/12/10.

  38. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015 Feb 20;33(6):559-66. PubMed PMID: 25547503. Epub 2014/12/31.

  39. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of treatment with sorafenib plus doxorubicin vs. sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 2019 Sep 5. PubMed PMID: 31486832. PMCID: PMC6735405. Epub 2019/09/06.

  40. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aube C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G, Group ST. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol. 2017 Dec;18(12): 1624-36. PubMed PMID: 29107679. Epub 2017/11/07.

  41. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y. Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. PubMed PMID: 25295214. PMCID: PMC4177084. Epub 2014/10/09.

  42. Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y. FGF19/ FGFR4 signaling contributes to the resistance of hepato-cellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017 Jan 9;36(1):8. PubMed PMID: 28069043. PMCID: PMC5223586. Epub 2017/01/11.

  43. Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer. 2018 Mar;7(1):1-19. PubMed PMID: 29662829. PMCID: PMC5892376. Epub 2018/04/18.

  44. Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, Hayato S, Kadowaki T, Okita K, Kumada H. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2016 Mar 15;22(6):1385-94. PubMed PMID: 26500236. Epub 2015/10/27.

  45. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Oku- saka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017 Apr;52(4):512-9. PubMed PMID: 27704266. PMCID: PMC5357473. Epub 2016/10/06.

  46. Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, Kumada H. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017 Sep;57(9):1138-47. PubMed PMID: 28561918. PMCID: PMC5575539. Epub 2017/06/01.

  47. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126): 1163-73. PubMed PMID: 29433850. Epub 2018/02/13.

  48. Deeks ED. Cabozantinib: A review in advanced hepato-cellular carcinoma. Target Oncol. 2019 Feb;14(1):107-13. PubMed PMID: 30767164. Epub 2019/02/16.

  49. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klumpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63. PubMed PMID: 29972759. Epub 2018/07/05.

  50. Rey JB, Launay-Vacher V, Tournigand C. Regorafenib as a single agent in the treatment of patients with gastrointestinal tumors: An overview for pharmacists. Target Oncol. 2015 Jun;10(2):199-213. PubMed PMID: 25213039. PM-CID: PMC4457933. Epub 2014/09/13.

  51. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, RESORCE investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. PubMed PMID: 27932229. Epub 2016/12/10.

  52. Heo YA, Syed YY. Regorafenib: A review in hepatocellular carcinoma. Drugs. 2018 Jun;78(9):951-8. PubMed PMID: 29915898. Epub 2018/06/20.

  53. Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim H-Y, Breder VV, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox JJ, Daniele B, Ebbinghaus S, Chen E, Siegel AB, Zhu AX, Cheng A-L, KEYNOTE investigators. Results of KEYNOTE-240: Phase 3 study of pembrolizumab (Pembro) vs. best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(15 Suppl):4004.

  54. Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J. Immunotherapy for hepatocellular carcinoma: Recent advances and future perspectives. Ther Adv Med Oncol. 2019;11:1758835919862692. PubMed PMID: 31384311. PMCID: PMC6651675. Epub 2019/08/07.

  55. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7(1):35-41. PubMed PMID: 18333159. PMCID: PMC2023920. Epub 2008/03/12.

  56. Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10(4):e0124434. PubMed PMID: 25923439. PMCID: PMC4414501. Epub 2015/04/30.

  57. Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, Ratti F, Marques HP, Soubrane O, Paredes AZ, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Prognosis after resection of Barcelona clinic liver cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification. Ann Surg Oncol. 2019 Oct;26(11):3693-700. PubMed PMID: 31267302. Epub 2019/07/04.

  58. Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: An update on ramucirumab. Expert Opin Biol Ther. 2013 Aug;13(8): 1187-96. PubMed PMID: 23803182. PMCID: PMC4131847. Epub 2013/06/28.

  59. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepato-cellular cancer: Results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. PubMed PMID: 24081937. Epub 2013/10/02.

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain